Abstract:Introduction: SSTR5 is one of five somatostatin receptors that mediate the inhibitory effect of somatostatin (SST) on insulin expression/secretion and islet neoplasia, yet the underlying mechanism remains elusive. Pancreatic and duodenal homeobox-1 (PDX-1) is a β-cell-specific transcription factor essential for pancreatic development and maintenance of β-cell functions. The purpose of this study is to determine whether SST/SSTR5 mechanism of action is regulated via PDX-1. Methods: The effect of SSTR5 agonist PRL-1980 on glucagon-like peptide 1 (GLP-1)-stimulated PDX-1 expression was examined by treating β-TC6 insulinoma cells with 0, 2.5, 5, 10 or 20 nM GLP-1 for 12 h with or without 30-min pretreatment of 100 nM PRL-1980, followed by Western blotting of PDX-1. The effect of p38 inhibitor SB202190 on GLP-1-stimulated PDX-1 expression was examined by treating β-TC6 cells with 20 nM GLP-1 for 12 h in the presence or absence of SB202190, followed by Western blotting of PDX-1. Mouse SSTR5 (mSSTR5) shRNA was generated by annealing and ligating the nucleotide 5'-GCCAAGATGAAGACAGTTA-3' from mSSTR5 cDNA into pSUPER vector at BglII and HindIII sites according to a Dharmacon protocol. The effect of SSTR5 knockdown on PDX-1 in MIN6 insulinoma cells was examined by transfecting mSSTR5 shRNA using Lipofectamine 2000, followed by Western blotting of PDX-1, Cyclin E, Cdk4, p53, p21 and p27 using appropriate antibodies. The effect of SSTR5 on PDX-1 in PANC-1 pancreas cancer cells was examined by co-transfecting HA-SSTR5 with Flag-PDX-1 into the cells using Lipofectamine 2000, followed by Western blotting of Flag-PDX-1. Immunoprecipitation/Western blotting was performed in β-TC6 cells treated with GLP-1 to examine the p38-PDX-1 interaction. The serine 61 and 269 residues of PDX-1 were mutated into alanine by performing site-directed mutagenesis. The effect of p38 on these mutants was examined by co-transfecting them with p38 into HEK-293 cells using Lipofectamine 2000, followed by Western blotting of PDX-1. Islet expression of PDX-1, insulin and PCNA in wild-type and SSTR5-/- mice was measured by immunofluorescent staining using appropriate antibodies. Results: 1. SSTR5 agonist inhibited GLP-1-stimulated increase of PDX-1 expression in β-TC6 cells; 2. GLP-1-stimulated PDX-1 expression was accompanied by kinase activation of p38 MAP kinase and p38-specific inhibitor SB202190 blocked GLP-1-stimulated increase of PDX-1 expression in β-TC6 cells; 3. SSTR5 agonist pretreatment inhibited both p38 kinase activation and PDX-1 expression stimulated by GLP-1; 4. Knockdown of SSTR5 by mSSTR5 shRNA enhanced PDX-1 expression in MIN6 cells, which was accompanied by increased expression of Cyclin E and Cdk4 and decreased expression of p53, p21 and p27; 5. co-transfection of SSTR5 with PDX-1 into PANC-1 cells resulted in down-regulation of PDX-1 in a dose-dependent manner; 6. GLP-1 induced an interaction of p38 with PDX-1 in β-TC6 cells; 7. mutation of serine 269 to alanine abolished the stabilizing effect of p38 on PDX-1 in HEK-293 cells; and 8. ablation of SSTR5 resulted in marked islet overexpression of PDX-1 which was accompanied by increased expression of insulin and PCNA in SSTR5-/- mice. Conclusion: These data suggest that p38 stabilizes PDX-1 through regulating its Ser 269 phosphorylation and that SSTR5 inhibits p38 kinase activation and thus down-regulates PDX-1 expression. We conclude that SST/SSTR5 exert their inhibitory effect via down-regulating PDX-1.

Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System.

Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas

Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs

Somatostatin-SSTR3-GSK3 modulates human T-cell responses by inhibiting OXPHOS

Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway

Conditional Deletion Of Shp2 Tyrosine Phosphatase In Thymocytes Suppresses Both Pre-Tcr And Tcr Signals

Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding

Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues

Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro

Genetic abnormalities of somatostatin receptors in pituitary tumors

Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action

SSTR5 Down-Regulates PDX-1 via Inhibition of P38 MAP Kinase

Molecular basis for the selective G protein signaling of somatostatin receptors

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

Casein kinase 2 phosphorylates and induces the SALL2 tumor suppressor degradation in colon cancer cells

Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility